Kelli L. Goss

Kelli L. Goss

Auto-generated profile, based on publicly available information

Kelli L. Goss

Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Iowa City, Iowa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
ECEmma Croushore
Emma Croushore
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
KGKelli L. Goss
Kelli L. Goss
EGElizabeth L. Geary
Elizabeth L. Geary
DGDavid Gordon
David Gordon
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the synthesis of deoxyribonucleosides and is required for DNA replication. Multiple types of cancer, including Ewing sarcoma tumors, are sensitive to RNR inhibitors or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. However, the polypharmacology and off-target effects of RNR inhibitors have complicated the identification of the mechanisms that regulate sensitivity and resistance to this class of drugs. Consequently, we used a conditional knockout (CRISPR/Cas9) and rescue approach to target RRM1 in Ewing sarcoma cells and identified that loss of the RRM1 protein results in the upregulation of the expression of multiple members of the activator protein-1 (AP-1) transcription factor complex, including c-Jun and c-Fos, and downregulation of c-Myc. Notably, overexpression of c-Jun and c-Fos in Ewing sarcoma cells is sufficient to inhibit cell growth and downregulate the expression of the c-Myc oncogene. We also identified that the upregulation of AP-1 is mediated, in part, by SLFN11, which is a replication stress response protein that is expressed at high levels in Ewing sarcoma. In addition, small-molecule inhibitors of RNR, including gemcitabine, and histone deacetylase inhibitors, which reduce the level of the RRM1 protein, also activate AP-1 signaling and downregulate the level of c-Myc in Ewing sarcoma. Overall, these results provide novel insight into the critical pathways activated by loss of RNR activity and the mechanisms of action of inhibitors of RNR. Significance: RNR is the rate-limiting enzyme in the synthesis of deoxyribonucleotides. Although RNR is the target of multiple chemotherapy drugs, polypharmacology and off-target effects have complicated the identification of the precise mechanism of action of these drugs. In this work, using a knockout-rescue approach, we identified that inhibition of RNR upregulates AP-1 signaling and downregulates the level of c-Myc in Ewing sarcoma tumors.

1 July 2019
Verified
Conference Paper
Closed access
DGDavid Gordon
David Gordon
KGKelli Goss
Kelli Goss
SKStacia Koppenhafer
Stacia Koppenhafer
Ewing sarcoma is a highly aggressive bone and soft tissue cancer that is caused by the EWS-FLI1 fusion protein. The treatment of Ewing sarcoma has changed very little in the past two decades and novel treatment approaches are needed. We recently identified that Ewing sarcoma cells are uniquely vulnerable to inhibitors of ribonucleotide reductase (RNR), the rate limiting enzyme in the synthesis of deoxyribonucleotides. We subsequently found that the inhibition of checkpoint kinase 1 (CHK1) increases the sensitivity of Ewing sarcoma cells to inhibitors of RNR, such as gemcitabine. The ATR-CHK1 pathway, from a mechanistic standpoint, regulates multiple stages of the cell cycle, including S-phase, the G2/M transition, and M phase. In the current work, we used cell synchronization to identify that the inhibition of CHK1 in S-phase cells results in premature entry into mitosis and cell death. Similarly, the inhibition of ATR serine/threonine kinase (ATR), the upstream activator of CHK1, also causes Ewing sarcoma cells to inappropriately enter mitosis. Moreover, we have found in Ewing sarcoma cells that this aberrant entry into mitosis is mediated, in part, by cyclin dependent kinase 1 (CDK1). In addition, activation of CDK1 by inhibiting the WEE1 kinase with AZD1775 also results in entry into mitosis and cell death in Ewing sarcoma cells. Currently, ongoing work is focused on the in vivo testing of gemcitabine in combination with CHK1 and WEE1 inhibitors as a novel therapeutic approach for the treatment of Ewing sarcoma. Citation Format: David Gordon, Kelli Goss, Stacia Koppenhafer. Inhibition of CHK1 sensitizes Ewing sarcoma cells to CDK1-dependent cell death in S-phase [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2956.

19 July 2023
Verified
Other
Open access
PDF file
ECEmma Croushore
Emma Croushore
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
KGKelli L. Goss
Kelli L. Goss
EGElizabeth L. Geary
Elizabeth L. Geary
DGDavid Gordon
David Gordon
Treatment of EW8-RRM1-KO cells with prexasertib.

19 July 2023
Verified
Other
Open access
PDF file
ECEmma Croushore
Emma Croushore
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
KGKelli L. Goss
Kelli L. Goss
EGElizabeth L. Geary
Elizabeth L. Geary
DGDavid Gordon
David Gordon
Dependency of Ewing sarcoma cells on RRM1 and RRM2.


19 July 2023
Verified
Other
Open access
PDF file
ECEmma Croushore
Emma Croushore
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
KGKelli L. Goss
Kelli L. Goss
EGElizabeth L. Geary
Elizabeth L. Geary
DGDavid Gordon
David Gordon
Gene set enrichment analysis of genes up- and down-regulated in the EW8-RRM1-KO cells after removal of doxycycline.